Glioma and post-translational modifications: A complex relationship

Pienkowski, Tomasz; Kowalczyk, Tomasz; Cysewski, Dominik; Kretowski, Adam; Ciborowski, Michal

doi:10.1016/j.bbcan.2023.189009

Cited by 4 publications

(3 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leveraging genomic technologies, such as next-generation sequencing (NGS), along with other omics techniques like proteomics and metabolomics [ 178 – 180 ], will enable more precise tumor profiling and pave the way for personalized immunotherapies. Growing interest in machine learning models for biomarker research [ 181 ] adds another layer of potential.…”

Section: Discussionmentioning

confidence: 99%

Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review

Golonko,

Pienkowski,

Swislocka

et al. 2024

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

Immunotherapy is emerging as a promising avenue in oncology, gaining increasing importance and offering substantial advantages when compared to chemotherapy or radiotherapy. However, in the context of immunotherapy, there is the potential for the immune system to either support or hinder the administered treatment. This review encompasses recent and pivotal studies that assess the influence of dietary elements, including vitamins, fatty acids, nutrients, small dietary molecules, dietary patterns, and caloric restriction, on the ability to modulate immune responses. Furthermore, the article underscores how these dietary factors have the potential to modify and enhance the effectiveness of anticancer immunotherapy. It emphasizes the necessity for additional research to comprehend the underlying mechanisms for optimizing the efficacy of anticancer therapy and defining dietary strategies that may reduce cancer-related morbidity and mortality. Persistent investigation in this field holds significant promise for improving cancer treatment outcomes and maximizing the benefits of immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review

Golonko,

Pienkowski,

Swislocka

et al. 2024

Cell Death Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Glioma is the most commonly observed brain tumor and is characterized by high malignancy, frequent recurrence, intractable drug resistance, and challenging therapeutic strategies [ 65 – 67 ]. Elevated expression of CELF1 has been found to correlate with unfavorable overall survival outcomes in glioma patients.…”

Section: Celf1 and Related Diseasesmentioning

confidence: 99%

Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review

Qin,

Shi,

Chen

et al. 2024

Cell Mol Biol Lett

View full text Add to dashboard Cite

RNA-binding proteins (RBPs) are kinds of proteins with either singular or multiple RNA-binding domains (RBDs), and they can assembly into ribonucleic acid–protein complexes, which mediate transportation, editing, splicing, stabilization, translational efficiency, or epigenetic modifications of their binding RNA partners, and thereby modulate various physiological and pathological processes. CUG-BP, Elav-like family 1 (CELF1) is a member of the CELF family of RBPs with high affinity to the GU-rich elements in mRNA, and thus exerting control over critical processes including mRNA splicing, translation, and decay. Mounting studies support that CELF1 is correlated with occurrence, genesis and development and represents a potential therapeutical target for these malignant diseases. Herein, we present the structure and function of CELF1, outline its role and regulatory mechanisms in varieties of homeostasis and diseases, summarize the identified CELF1 regulators and their structure–activity relationships, and prospect the current challenges and their solutions during studies on CELF1 functions and corresponding drug discovery, which will facilitate the establishment of a targeted regulatory network for CELF1 in diseases and advance CELF1 as a potential drug target for disease therapy. Graphical Abstract

show abstract

“…Although significant and encouraging progress has been made in exploring the heterogeneity between and within tumors, leveraging this heterogeneity for diagnosis and investigating the tumor microenvironment has further advanced immunotherapy ( 4 ). Nevertheless, glioma patients have benefited minimally from these developments ( 5 ). Therefore, urgent research efforts are required to identify novel and more suitable approaches to combat gliomas ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Single cell sequencing revealed the mechanism of CRYAB in glioma and its diagnostic and prognostic value

Cai,

Zhao,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundWe explored the characteristics of single-cell differentiation data in glioblastoma and established prognostic markers based on CRYAB to predict the prognosis of glioblastoma patients. Aberrant expression of CRYAB is associated with invasive behavior in various tumors, including glioblastoma. However, the specific role and mechanisms of CRYAB in glioblastoma are still unclear.MethodsWe assessed RNA-seq and microarray data from TCGA and GEO databases, combined with scRNA-seq data on glioma patients from GEO. Utilizing the Seurat R package, we identified distinct survival-related gene clusters in the scRNA-seq data. Prognostic pivotal genes were discovered through single-factor Cox analysis, and a prognostic model was established using LASSO and stepwise regression algorithms. Moreover, we investigated the predictive potential of these genes in the immune microenvironment and their applicability in immunotherapy. Finally, in vitro experiments confirmed the functional significance of the high-risk gene CRYAB.ResultsBy analyzing the ScRNA-seq data, we identified 28 cell clusters representing seven cell types. After dimensionality reduction and clustering analysis, we obtained four subpopulations within the oligodendrocyte lineage based on their differentiation trajectory. Using CRYAB as a marker gene for the terminal-stage subpopulation, we found that its expression was associated with poor prognosis. In vitro experiments demonstrated that knocking out CRYAB in U87 and LN229 cells reduced cell viability, proliferation, and invasiveness.ConclusionThe risk model based on CRYAB holds promise in accurately predicting glioblastoma. A comprehensive study of the specific mechanisms of CRYAB in glioblastoma would contribute to understanding its response to immunotherapy. Targeting the CRYAB gene may be beneficial for glioblastoma patients.

show abstract

Glioma and post-translational modifications: A complex relationship

Cited by 4 publications

References 132 publications

Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review

Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review

Curriculum vitae of CUG binding protein 1 (CELF1) in homeostasis and diseases: a systematic review

Single cell sequencing revealed the mechanism of CRYAB in glioma and its diagnostic and prognostic value

Contact Info

Product

Resources

About